PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 140

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis to 2022″. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The projected drivers of market growth include increased patient awareness of HCV, broader HCV screening recommendations, the shift in American medicine toward preventative care, and the launch of next-generation HCV therapies.

Vertex’s Incivek is the current market leader. It was among the first DAA HCV therapies launched in the US. Incivek’s improved efficacy over the previous standard of care (i.e., peginterferon and ribavirin combination therapy) in the treatment of the most prevalent HCV genotype in the US, HCV GT1, enabled the drug to quickly capture the market. The adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the US

PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17

4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 US 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 24

5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 27
5.3 Product Profiles - Major Brands 29
5.3.1 Incivek (telaprevir) 29
5.3.2 Victrelis (boceprevir) 34
5.3.3 Pegasys (peginterferon alfa-2a) 38
5.3.4 PegIntron (peginterferon alfa-2b) 43
5.3.5 Copegus, Rebetol, and Generic Ribavirin 47
5.3.6 Therapeutic Class: Interferon 50

6 Opportunity and Unmet Need 51
6.1 Overview 51
6.2 Unmet Needs 52
6.2.1 Unmet Need: Treatment Tolerability 52
6.2.2 Unmet Need: Efficacy 52
6.2.3 Unmet Need: Disease Awareness 53
6.2.4 Unmet Need: Treatment Cost 54
6.2.5 Unmet Need: Shorter Treatment Duration 54
6.2.6 Unmet Need: Simplified Treatment Regimens 55
6.3 Unmet Needs Gap Analysis 56
6.4 Opportunities 57
6.4.1 Opportunity: Pan-genotypic HCV Regimen 57
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 57
6.4.3 Opportunity: Involvement of Immune System 58

7 Pipeline Assessment 59
7.1 Overview 59
7.2 Promising Drugs in Clinical Development 60
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 62
7.2.2 Simeprevir 72
7.2.3 ABT-450 plus ABT-267 and ABT-333 80
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 87
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 95
7.2.6 Other Drug Classes 103

8 Market Outlook 106
8.1 US 106
8.1.1 Forecast 106
8.1.2 Key Events 111
8.1.3 Drivers and Barriers 111

9 Appendix 116
9.1 Bibliography 116
9.2 Abbreviations 125
9.3 Methodology 127
9.4 Forecasting Methodology 127
9.4.1 Percent Drug-Treated Patients 127
9.4.2 Patient Warehousing 128
9.4.3 Drugs Included in Each Therapeutic Class 128
9.4.4 Launch and Patent Expiry Dates 129
9.4.5 General Pricing Assumptions 130
9.4.6 Individual Drug Assumptions 130
9.4.7 Generic Erosion 132
9.4.8 Selection of Pipeline Agents 132
9.4.9 Pricing of Pipeline Agents 133
9.5 Physicians and Specialists Included in this Study 136
9.6 Survey of Prescribing Physicians 138
9.7 About the Authors 139
9.7.1 Author 139
9.7.2 Global Head of Healthcare 139
9.8 About GlobalData 140
9.9 Contact Us 140
9.10 Disclaimer 140

List Of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 21
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 28
Table 8: Product Profile - Incivek 30
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 30
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 31
Table 11: Common Incivek Adverse Drug Reactions 32
Table 12: Incivek SWOT Analysis, 2012 33
Table 13: Product Profile - Victrelis 34
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 35
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 36
Table 16: Victrelis SWOT Analysis, 2012 37
Table 17: Product Profile - Pegasys 39
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 40
Table 19: Pegasys SWOT Analysis, 2012 42
Table 20: Product Profile - PegIntron 44
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 44
Table 22: PegIntron SWOT Analysis, 2012 46
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 48
Table 24: Ribavirin SWOT Analysis, 2012 49
Table 25: Summary of Minor Therapeutic Classes, 2012 50
Table 26: Overall Unmet Needs - Current Level of Attainment 51
Table 27: Clinical Unmet Needs - Gap Analysis, 2012 56
Table 28: HCV - Pipeline, 2012 60
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 61
Table 30: Gilead's Sofosbuvir Ongoing Clinical Trials of Interest 63
Table 31: Product Profile - Sofosbuvir 64
Table 32: Sofosbuvir's Most Common Adverse Effects 67
Table 33: Sofosbuvir SWOT Analysis, 2012 71
Table 34: Janssen's Simeprevir Ongoing Clinical Trials of Interest 73
Table 35: Product Profile - Simeprevir 74
Table 36: PILLAR Clinical Trial Results 74
Table 37: Adverse Events Observed in PILLAR Clinical Trial 75
Table 38: Simeprevir SWOT Analysis, 2012 79
Table 39: AbbVie's Combination Therapy Ongoing Clinical Trials of Interest 81
Table 40: Product Profile - AbbVie Combination Therapy 82
Table 41: AVIATOR Clinical Trial Results 82
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 86
Table 43: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 88
Table 44: Product Profile - Faldaprevir 89
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 89
Table 46: Faldaprevir SWOT Analysis, 2012 94
Table 47: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 96
Table 48: Product Profile - Daclatasvir 97
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 97
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 98
Table 51: Daclatasvir Triple Therapy Adverse Events 99
Table 52: Daclatasvir SWOT Analysis, 2012 102
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 103
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 104
Table 55: Sales Forecasts ($m) for HCV in the US, 2012-2022 109
Table 56: Key Events Impacting Sales for HCV in the US, 2012 111
Table 57: US HCV Market - Drivers and Barriers, 2012 111
Table 58: Key Launch Dates 129
Table 59: Key Patent Expiries 129
Table 60: Physicians Surveyed, By Country 138

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 60
Figure 4: Sales for HCV Therapeutics in the US by Drug Class, 2012-2022 110

  • Overcoming Obesity
    In today’s world where there are countries struggling to overcome famine and shortage of food there are others who are increasingly getting populated with obese people. Obesity is one of the key problem many are facing across the world. It is a result of either improper lifestyle and food habits or is completely hereditary. In [...]
  • The Booming Market of Carbon Fibre
    The speed at which the Carbon Fibre Industry is growing it is sure to be one of the most profitable industry in the years to come. The sales of carbon fibre tow is expected to increase from $1.6 billion in 2011 to $4.5 billion in 2020. The overall The global demand for carbon fibre tow [...]
  • Incentivising Research & Development Activities
    Research and Development (R&D) is the base of innovation, competitiveness and economic performance. Any company or a country that seeks to be ahead of its competitors need to invest heavily in setting up an active R&D wing. In today’s world everything is technology oriented.  People are coming up with new ideas, products and newer ways [...]
  • Global Cystic Fibrosis Market Propelled by Technological Advancement
    With increasing prevalence of cystic fibrosis and its growing awareness among people, the global market for cystic fibrosis is expected to grow at a steady pace. Cystic fibrosis is a genetic condition where the lungs and digestive system becomes clogged with excess mucus. This condition is more common among Caucasian population than people of Asian [...]
  • Bright Prospects Ahead for the SONAR Systems and Technology Market
    With advancement of technology, the global SONAR systems and technology market is increasing at a rapid pace. SONAR which is an acronym for SOund Navigation And Ranging is a technique that uses sound propagation to navigate and communicate with objects on or under the surface of the water, such as other vessels. In 2014, the [...]
  • The Boom In Women Infertility Market
  • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Retaining the Hard-Won Consumers
  • With the increase in mobile phone usage different operators are coming up with different plan in order to cater to users of all age-group with various data plan to choose from. With the maturing mobile market operators are coming up …

  • To bring in Photography to the Real World Visual Supply Co Acquires Artifact Uprising
  • Visual Supply Co, VSCO has brought a Denver-based startup, Artifact Uprising, which is focused on bringing photographers’ work from the digital hubs on regular basis by modern creatives to the real world as prints and tangible books. Artifact Uprising is …

  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Global Epinephrine Autoinjector Market 2015-2019
    Published: 25-Mar-2015        Price: US $2500 Onwards        Pages: 89
    Epinephrine, commonly known as adrenaline, is a hormone secreted by the medulla of the adrenal gland and circulated through the bloodstream. It acts as a neurotransmitter that responds to brain signals. These signals trigger responses such as threat, excitement, danger, emotion, and stress, which stimulate the adrenal gland to secrete epinephrine in response to the changes in the body. Adrenaline prepares the body to fight against anaphylactic shock that occurs due to allergic reactions, cardiac......
  • Duloxetine – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)
    Published: 23-Mar-2015        Price: US $1400 Onwards        
    Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. !NOW WITH ‘USA VIEW'! "The most extensive source of patent information available." Product Portfolio Manager - Dr Reddys Laboratories "The database is reliable, frequently updated, we......
  • Nateglinide – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)
    Published: 23-Mar-2015        Price: US $1400 Onwards        
    Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. !NOW WITH ‘USA VIEW'! "The most extensive source of patent information available." Product Portfolio Manager - Dr Reddys Laboratories "The database is reliable, frequently updated, we......
  • Tigecycline – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)
    Published: 23-Mar-2015        Price: US $1400 Onwards        
    Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. !NOW WITH ‘USA VIEW'! "The most extensive source of patent information available." Product Portfolio Manager - Dr Reddys Laboratories "The database is reliable, frequently updated, we......
  • Anacetrapib – Comprehensive patent search
    Published: 23-Mar-2015        Price: US $7500 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Ciclesonide – Comprehensive patent search
    Published: 23-Mar-2015        Price: US $7500 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Eplerenone – Comprehensive patent search
    Published: 23-Mar-2015        Price: US $6200 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Iloprost – Comprehensive patent search
    Published: 23-Mar-2015        Price: US $9300 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Fosamprenavir – Comprehensive patent search
    Published: 23-Mar-2015        Price: US $7500 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs